AP-HP, Bicêtre Hospital
Le Kremlin-Bicêtre, 94275, France
NCT Number: NCT02041780
The purpose of this study is to determine if SWE and Fibrotest®/ Fibromax®, alone or associated, are effective methods to assess liver fibrosis in children.
Looking for future studies?
Notify MeUp to 18 year
All sexes
Interventional
Not applicable
Le Kremlin-Bicêtre, 94275, France
Liver biopsy will be the gold standard to assess fibrosis using Ishak score and morphometric evaluation of fibrosis. All children included will have a measure of liver stiffness using SWE with 5 measures performed in the area where the biopsy is performed and 5 measures in an other place in the liver. Fibrotest®/ Fibromax® will be performed on blood sample. All exams will be done within 1 month. diagnostic performance of SWE and Fibrotest®/ Fibromax® will be assessed respectively. algorithm using the results of both technics will be tested in order to test diagnostic performance and to obtain better performances.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-
Time frame: up to 1 month
Histology is the gold standard to evaluate liver fibrosis
Time frame: up 1 month
Time frame: up 1 month
Assistance Publique - Hôpitaux de Paris
Other
Non Invasive Assessment of Liver Fibrosis in Children: Evaluation of Diagnostic Performances of ShearWave Elastography (SWE) and Fibrotest®/ Fibromax® by Comparison With Fibrosis Score on Liver Biopsy
Acronym: SHEARWAVE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07069725
Digestive System Diseases, Fibrosis
Stockholm, Sweden
View Trial DetailsNCT05935488
Digestive System Diseases, Fibrosis
Norwich, Norfolk, United Kingdom
View Trial DetailsNCT06750276
Digestive System Diseases, Fibrosis
Chandler, Arizona, United States
View Trial DetailsNCT00326482
Chemically-Induced Disorders, Digestive System Diseases
Bethesda, Maryland, United States
View Trial Details